SNDX News and Press, Syndax Pharmaceuticals Inc. From 01/07/22

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass. , Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company...

Syndax Pharmaceuticals (NASDAQ:SNDX) announces that the European Commission has granted Orphan Drug Designation to SNDX-5613, an oral menin inhibitor, for the treatment of acute myeloid leukemia (AML). Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivit...

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia PR Newswire WALTHAM, Mass. , Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SND...

Syndax Pharmaceuticals (NASDAQ:SNDX) has priced its public offering of 3,157,144 shares of common stock, and pre-funded warrants to purchase 1,142,856 common shares. The public offering price of each share and warrant is $17.50 and $17.4999, respectively. Expected gross proceeds are ~$75.3M. ...

Syndax Announces Pricing of $75.3 Million Public Offering PR Newswire WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative...

Syndax Pharmaceuticals (NASDAQ:SNDX) shares are down 6% in after-hours trading after announcing plans for an underwritten public offering. The amount of the offering has yet to be determined. Syndax may sell to some investors pre-funded warrants to purchase shares of its common stoc...

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 - 55% overall response rate and 24% CR/CRh rate in relapsed/refractory acute leukemia patients w...

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease - 68% overall response rate and broad multiorgan clinical benefit observed in highly refractory patients treated ...

Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab PR Newswire WALTHAM, Mass. , Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust ...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation